Cardiovascular genetics

Cardiovascular genetics: are we there yet?

A C Sturm

Since 1900, cardiovascular disease has been the number one killer in the United States every year except 1918, the year of the great influenza pandemic. Cardiovascular disease claims more lives each year than the next five leading causes of death combined, which are cancer, chronic lower respiratory diseases, accidents, diabetes mellitus, influenza and pneumonia.1 Cardiovascular disease is also the leading cause of death in Europe, accounting for over 4 million deaths each year and, according to World Health Organization estimates, 16.6 million people around the globe die of cardiovascular disease each year.2 Based on the United States National Heart, Lung, and Blood Institute Family Heart Study, in its 44 year follow up of participants and a 20 year follow up of their offspring, coronary artery disease accounts for more than half of all cardiovascular events in men and women under the age of 75. Further, coronary artery disease is the single largest killer of men and women in America.3

CORONARY ARTERY DISEASE

Coronary artery disease has a complex aetiology, involving multiple genetic and environmental influences and interactions. In a recent review, Lusis estimates the total number of genes involved in cardiovascular disease by considering the risk factors for cardiovascular disease that are under genetic control.4 Some of these risk factors with a significant heritability include cholesterol levels, triglyceride levels, hypertension, obesity, diabetes, and the metabolic syndrome, all of which themselves have many genes involved in their susceptibility.5,6 Therefore, at least hundreds of genes are involved in the susceptibility to cardiovascular disease.7 The identification and characterisation of these genes has been a major undertaking and challenge for researchers. A recent call to arms from Sing et al.8 makes recommendations for what needs to be done to cope with these complexities, including developing new statistical methods to analyse the exponentially increasing amount of data generated by contemporary technology as well as training scientists for a “biocomplex future” and encouraging collaborations between researchers that help to study “how the parts are put together” in complex traits.

MEF2A

Much about the genetic basis of coronary artery disease remains unknown and the search for genes that cause major susceptibility in the development of coronary artery disease has been frustrating. In a recent Science report, Wang et al9 described a large family segregating an autosomal dominant form of coronary artery disease. Thirteen individuals in this family displayed coronary artery disease and nine of these thirteen patients developed acute myocardial infarction. A genome wide linkage scan identified a significant linkage to chromosome 15q26, a region containing approximately 93 genes, 43 of which were known genes. A member of the myocyte enhancer factor 2 transcription factors, MEF2A, became a strong candidate, since its mRNA has been detected in blood vessels during early mouse development.7 In all 10 living affected family members, a 21 base pair deletion in exon 11 of MEF2A was identified. Further, this deletion was not present in family members with normal phenotypes nor was it present in 119 individuals with normal angiograms. Wang et al9 also showed evidence that the deletion is a functional mutation that probably acts by a dominant negative mechanism, and immunostaining revealed a strong MEF2A protein signal within the endothelial cell layer of coronary arteries. However, Wang and his colleagues also reported that three other large families with coronary artery disease or myocardial infarction are not linked to this locus, and 50 patients, of unknown ages, with sporadic coronary artery disease or myocardial infarction did not have an MEF2A mutation. Therefore, MEF2A may only be a rare cause of coronary artery disease and myocardial infarction, accounting for only a small percentage of incidences of the disease overall.

Optimists would like to think that MEF2A may be as important as the BRCA1 and BRCA2 genes in the development of the hereditary breast and ovarian cancer syndromes. Pessimists, on the other hand, will counter that this may only be a private mutation found in just one single family. Possibly, MEF2A will fall somewhere in between these two extremes. Future studies will be necessary to determine the prevalence of patients having coronary artery disease or myocardial infarction with MEF2A mutations as well as whether single nucleotide polymorphisms within this gene with smaller effects may be associated with common coronary artery disease and myocardial infarction.

OTHER LOCI LINKED TO CARDIOVASCULAR DISEASE

Whether you are an optimist or a pessimist, the discovery of the first autosomal dominant gene for coronary artery disease and myocardial infarction is truly exciting. To date, there have been just four other published studies that have identified loci linked to cardiovascular disease. Linkage to two loci likely to contribute to premature coronary artery disease, one on chromosome 2q21.1–22 and another on Xq23–26, were found using a Finnish population.10 A susceptibility locus for coronary artery disease on chromosome 16p13.3 was identified in Indo-Mauritians.11 A whole genome scan in 513 western European families found evidence for linkage to myocardial infarction in a region on chromosome 14q11.2–12.12 And the acute coronary syndrome, consisting of myocardial infarction and unstable angina, has been linked to 2q36–q37.3.13

PROBLEMS IN GENE IDENTIFICATION

Although the above linkage reports provide a definitive starting place for the identification of potential candidate genes, and the availability of the genomic sequence for these starting places should facilitate gene identification, the specific genes have yet to be found. In fact, up until the Wang et al9 report, the majority of genes known to be involved in coronary artery disease have been identified using association studies, either using a candidate gene approach or by conducting whole genome association studies that take advantage of the hundreds of thousands of single nucleotide polymorphisms that span our genome.

Critics have conceded that findings from many genetic association studies are inconsistent and cannot be
replicated, and that these studies should be restricted to the study of polymorphisms that have been shown to have a direct effect on gene function. In fact, in a recent review of genetic association studies, Hirschhorn et al found that over 600 positive associations between common gene variants and disease have been reported. Of the putative associations which have been studied three or more times, only 3.6% have been consistently replicated. Many have offered their assessment of association studies, and of why type I errors (false positives) seem to abound. There are several reasons for the inability to replicate genetic associations. These include population stratification, modification of the association by other genetic or environmental factors that vary between groups studied, genotyping error rates that differ between cases and controls, absence of power leading to false negative results, failure to exclude chance as an explanation for association in some studies, and publication bias, where several studies are undertaken but only positive results are reported, which some claim is the most likely reason for failure to replicate. 

**GENOME WIDE CASE CONTROL STUDIES**

While there are definite reasons to be pessimistic about association studies, a number of them have provided strong evidence that genome wide case control studies are powerful tools in the identification of genes related to common diseases such as coronary artery disease. One recent large scale case control study identified a candidate gene, lymphotoxin-α, associated with susceptibility to myocardial infarction and two genetic variants within this gene were proven to affect its expression level and genetic variants within this gene were studied, genotyping error rates that differ between cases and controls, absence of power leading to false negative results, failure to exclude chance as an explanation for association in some studies, and publication bias, where several studies are undertaken but only positive results are reported, which some claim is the most likely reason for failure to replicate. 

The strongest association found was with the A387P variant in thrombomodulin-4, conferring a greater than twofold increase in the odds of myocardial infarction. This association was also reported in this group’s previous report and has since been replicated in a number of studies. Further, functional genomics studies performed by this group (currently in press) have shown that this variant is a gain of function mutation that interferes with endothelial cell adhesion and proliferation, and is therefore biologically relevant. 

While McCarthy et al also report on novel genetic associations with coronary artery disease in this manuscript, the validity of these associations remains to be seen and will require future replication studies. So, while criticisms of association studies are ever present, the authors' conclusion that case control association studies are effective in generating hypotheses for candidate genes in coronary artery disease rings true. 

**THE PURPOSE OF GENETIC EVALUATION**

Finally, then, the question remains: are we there yet? The answer to this question depends on what your own definition of “there” is. No, not every susceptibility gene or single nucleotide polymorphism within these susceptibility genes associated with coronary artery disease is known. However, we must ask ourselves, what is the primary goal of all this genomic research? And we must answer this question by stating that the reason for this research is to reduce the morbidity and mortality caused by the disease in question. Importantly, 50% of men and 63% of women who died suddenly from coronary artery disease had no previous symptoms of this disease. For this reason alone, the utility of cardiovascular genetics clinics whose main goals are identification of those at increased risk, subsequent modification of this risk, and therefore prevention of coronary artery disease, must be recognised. Obtaining a comprehensive family history should be an integral component of any disease prevention programme. The significance of the familial occurrence of coronary artery disease has been a focus of research for at least 50 years, with a positive family history of coronary artery disease emerging as an independent predictor of risk in the development of coronary artery disease even when other risk factors are considered. 

Applying what we know now about cardiovascular genetics in a clinical setting to prevent this leading cause of death is a reality. In a recent review from Scheuerman, the components that should be included in a genetic evaluation for coronary artery disease are recommended, including genetic risk assessment, risk factor modification, early detection strategies, and genetic counselling and education. Risk assessment includes pedigree analysis, personal medical history, physical examination, laboratory testing, and early detection techniques, which not only serve to help in risk stratification, but also serve to screen those individuals already in greater than average risk categories based on family history. These techniques will allow aggressive risk factor modification when necessary or, when unnecessary, may lead to patient reassurance, comparative to colonoscopy in screening for colon cancer. The goal of the genetic evaluation for coronary artery disease then is to provide the patient, through genetic counselling and education, with an individualised strategy for early detection and prevention that fits with their preferences, and potentially includes both lifestyle changes involving diet, weight control, exercise, and smoking cessation, as well as targeted drug therapy in appropriate cases. 

**CONCLUSION**

So, while we may not be completely “there” yet in terms of understanding the complex genetics of cardiovascular disease, there are definite ways in which morbidity and mortality due to cardiovascular disease can be reduced by genetic counselling of at risk individuals in cardiovascular genetics clinics. Because of the high prevalence of cardiovascular disease, the moment we are “there”, genetic counsellors, cardiovascular geneticists, and cardiologists should expect a tidal wave of demand, one that would dwarf that for even clinical cancer genetics. Now would therefore be the time to think of viable strategies to involve primary caregivers in helping with the 21st century practice of molecular based cardiovascular risk assessment and management. 

**REFERENCES**

COMMENTARY


PTEN hamartoma tumour syndrome

Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome

R Pilarski, C Eng

Since consensus operational diagnostic criteria for Cowden syndrome (MIM 158350) were first established in 1995, our understanding of this complex disease—and the spectrum of disorders related to it by virtue of also having germline mutations in the PTEN tumour suppressor gene—has continued to evolve. This was reflected in a commentary1 in this journal in 2000 in which it was proposed that endometrial cancer and renal cell carcinoma be added to the operational diagnostic criteria for Cowden syndrome (table 1). This updated commentary is intended to provide a review of significant changes in our understanding of the growing group of disorders, which are known to be caused by germline mutations in PTEN on 10q23.3, and which have been termed the PTEN hamartoma tumour syndrome.

THE CLINICAL SPECTRUM OF THE PTEN HAMARTOMA TUMOUR SYNDROME

Cowden syndrome is a complex disorder with malignant and benign (hamartomatous) lesions affecting derivatives of all three germ cell layers. Major organs involved include the breast, thyroid, uterus, brain, and mucocutaneous tissues.2 It has been estimated to affect about 1 in 200 000 individuals,3 although this is probably an underestimate given the difficulty in diagnosis presented by this highly variable disease and the fact that many component features in and of themselves can occur in the general population. Penetrance is related to age, with most patients presenting by their late twenties with at least the mucocutaneous lesions of this disorder, which are reportedly seen in 99% of affected individuals. The
lifetime risk for breast cancer in Cowden syndrome is estimated to be 25–50%, with an average age of diagnosis between 38 and 46 years old. The risk for thyroid cancer (typically follicular, but occasionally papillary) is approximately 10%, while the risk for endometrial cancer, although not well established, has been estimated to be 5–10%. The frequency of germline PTEN mutations in Cowden syndrome probands ascertained by the strict clinical diagnostic criteria are robust even at the molecular level. Nonetheless, it became obvious that other types of alterations in PTEN might account for the remainder of Cowden syndrome.11

An operational diagnosis of Cowden syndrome is made if an individual meets any one of the following criteria:

1. Pathognomic mucocutaneous lesions alone if there are: Six or more facial papules, of which three or more must be trichilemmoma, or Cutaneous facial papules and oral mucosal papillomatosis, or Oral mucosal papillomatosis and acne rosacea, or Six or more palm planter keratoses

2. Two major criteria but one must be either macrocephaly or Lhermitte-Duclos disease

3. One major and three minor criteria

4. Four minor criteria

In a family in which one individual meets the diagnostic criteria for Cowden syndrome, other relatives are considered to have a diagnosis of Cowden syndrome if they meet any of the following criteria:

1. A pathognomonic mucocutaneous lesion

2. Any one major criterion with or without minor criterion

3. Two minor criteria

Table 1 International Cowden Consortium operational criteria for the diagnosis of Cowden syndrome. Ver 2000

<table>
<thead>
<tr>
<th>Pathognomonic criteria</th>
<th>Major criteria</th>
<th>Minor criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mucocutaneous lesions:</td>
<td>Breast cancer</td>
<td>Other thyroid lesions (for example, goitre)</td>
</tr>
<tr>
<td>Trichilemmomas, facial</td>
<td>Thyroid cancer, especially follicular thyroid cancer</td>
<td>Mental retardation (IQ &lt; 75)</td>
</tr>
<tr>
<td>Acral keratoses</td>
<td>Macrocephaly (occipital frontal circumference &gt;97th percentile)</td>
<td>Hamartomatic intestinal polyps</td>
</tr>
<tr>
<td>Papillomatous lesions</td>
<td>Lhermitte-Duclos disease, defined as presence of a cerebellar dysplastic gangliocytoma</td>
<td>Fibrocystic disease of the breast</td>
</tr>
<tr>
<td>Mucosal lesions</td>
<td>Endometrial carcinoma</td>
<td>Lipomas</td>
</tr>
</tbody>
</table>

COWDEN SYNDROME COMPONENT NEOPLASIAS

Lhermitte-Duclos disease, or dysplastic gangliocytoma of the cerebellum, is a hamartomatic overgrowth believed to be a component feature of Cowden syndrome. Clinically, patients with Lhermitte-Duclos disease may present with ataxia, increased intracranial pressure, and seizures. Although familial cases are known, Lhermitte-Duclos disease is usually sporadic, and the exact contribution of Cowden syndrome to the overall incidence of Lhermitte-Duclos disease is unknown. In a recent report, PTEN mutations were identified in tissues from Lhermitte-Duclos disease lesions from 15 (83%) of 18 unselected patients. Immunostaining also showed reduced or absent PTEN expression in 11 (78%) of 14 samples analysed and, more importantly, they were shown to
have increased Akt phosphorylation which reflects downstream dysfunction leading to inability to undergo apoptosis and G1 cell cycle arrest.\textsuperscript{21} All individuals with mutations had adult onset Lhermitte-Duclos disease, while the three patients without mutations had the childhood onset disease. This corroborates two previous reports from the literature in which germline PTEN mutations and signs of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome were absent in patients with childhood-onset Lhermitte-Duclos disease.\textsuperscript{22, 23} Germline DNA was available from six of the adult patients, and testing confirmed the presence of a germline mutation in each. Two of the six had features of Cowden syndrome, one did not, and three did not have available clinical information. These results confirm that adult onset Lhermitte-Duclos disease is a major component of Cowden syndrome, and that individuals with adult onset Lhermitte-Duclos disease should be evaluated carefully for signs of Cowden syndrome.\textsuperscript{17} It should routinely be offered PTEN gene testing, even in the absence of other signs of PTEN hamartoma tumour syndrome. While these data are almost compelling to move Lhermitte-Duclos disease to the pathognomonic category in the operational diagnostic criteria, we have left it in the major criteria section for now (table 1).

**GERMLINE PTEN MUTATION FREQUENCY AND SPECTRUM**

Promoter and deletion mutations. Germline PTEN mutations have been identified in 80\% of individuals meeting diagnostic criteria for Cowden syndrome and in 50–60\% of patients with a diagnosis of Bannayan-Riley-Ruvalcaba syndrome, using PCR based mutation analysis of the coding and flanking intronic regions of the gene.\textsuperscript{16} Whether the remaining patients have undetected PTEN mutations is an unproven hypothesis; genes is not definitively known, although it is believed that Cowden syndrome is not genetically heterogeneous.\textsuperscript{8} Scanning the 600 base pair full promoter region has recently revealed germline PTEN promoter mutations in 9 (\textpm{}10\%) of 95 Cowden syndrome patients who had previously been found to be mutation negative on testing of the coding and flanking intronic regions.\textsuperscript{24} None of these mutations were found among 372 control alleles studied. All nine patients had breast cancer or benign breast disease, or both, but otherwise relatively few other organs were involved. Protein lysates from peripheral blood lymphoblastoid cells from five of these nine patients were found to have decreased levels of normal PTEN protein and concordant increase or laddering of alternate bands on western blotting which were not observed in 32 control samples or 23 mutation negative samples. Reflecting PTEN dysfunction, germline protein from individuals with promoter mutations had increased phosphorylated Akt. Further, large germline PTEN deletions encompassing all or part of the gene were noted in 3 (11\%) of 27 Bannayan-Riley-Ruvalcaba syndrome patients studied (two Bannayan-Riley-Ruvalcaba syndrome/Bannayan-Riley-Ruvalcaba syndrome/Cowden syndrome overlap). Protein analysis from one of these patients found a 50\% decrease in PTEN protein level and concomitant increase in phosphorylated Akt.

Of note, only Cowden syndrome probands were found to harbour germline PTEN promoter mutations.\textsuperscript{26} No promoter mutations have been found in Bannayan-Riley-Ruvalcaba syndrome to date although the work is ongoing. In contrast, only Bannayan-Riley-Ruvalcaba syndrome (or Cowden syndrome/Cowden syndrome/Cowden syndrome overlap) patients have been found to have large deletions or rearrangements involving PTEN.\textsuperscript{27} 24 25

Finally, a de novo case of Cowden syndrome presenting with Lhermitte-Duclos disease in adulthood was found to have the de novo germline PTEN mutation c.179dele arise on the paternal chromosome.\textsuperscript{26} Whether the majority of cases of Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, and PTEN hamartoma tumour syndrome arise on paternal chromosomes is unknown and is a question which needs to be investigated.

**MANAGEMENT OF PTEN HAMARTOMA TUMOUR SYNDROME**

Management for Cowden syndrome is primarily focused on the cancer risks. Clinical breast examinations are recommended annually for women beginning at age 25, and annual mammography starting at age 30–35. Breast cancer has been reported in men with Cowden syndrome, and it is thus recommended that they practise regular breast self examinations. Men and women should have an annual physical examination beginning at age 18, with careful attention paid to the skin and neck region. A baseline thyroid ultrasound is also recommended at age 18 (with consideration of annual thyroid ultrasound thereafter). Women with Cowden syndrome should also undergo endometrial screening involving annual blind (repel) biopsies starting at age 35–40, and annual endometrial ultrasound after menopause, with biopsy of suspicious lesions. Annual urine analysis for the detection of renal cell carcinoma is also recommended along with annual urine cytology and renal ultrasound if there is a family history of renal cancer.\textsuperscript{27}

While cancer risks in Bannayan-Riley-Ruvalcaba syndrome were initially felt to be similar to those of the general population, confirmation that >60\% of Bannayan-Riley-Ruvalcaba syndrome is allelic to Cowden syndrome and due to PTEN gene mutations has led to the recommendation that Bannayan-Riley-Ruvalcaba syndrome patients should conservatively be managed according to Cowden syndrome guidelines. While the gastrointestinal hamartomatous polyposis seen in Bannayan-Riley-Ruvalcaba syndrome does not predispose to significantly increased cancer risks, patients should be monitored for complications of the polyps themselves, such as intussusception.

It has only recently been shown that a subset of patients with Proteus syndrome and Proteus-like syndrome have PTEN mutations, and at this point it is not clear whether cancer risks associated with Cowden syndrome pertain to these patients as well. To be conservative, it might be prudent to follow Cowden syndrome screening guidelines for patients with PTEN mutation positive Proteus syndrome and Proteus-like syndrome as well.

**CONCLUSIONS**

The recent identification of germline PTEN deletions and promoter mutations indicates that these types of mutation account for approximately 10\% each of patients with Cowden syndrome and patients with Bannayan-Riley-Ruvalcaba syndrome who are mutation-negative on PCR based analysis, even using direct sequencing, of exons 1–9 and flanking intronic regions. Thus, all in all, the germline PTEN mutation frequencies for Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome would approach 85–90\% and 65\%, respectively. Because promoter mutations have only been noted in Cowden syndrome up until now, it is possible that promoter analysis should be limited to Cowden syndrome. Similarly, should large deletions continue to be observed only in Bannayan-Riley-Ruvalcaba syndrome/Cowden syndrome/Bannayan-Riley-Ruvalcaba syndrome overlap, and not Cowden syndrome, perhaps deletion analysis should only be offered in Bannayan-Riley-Ruvalcaba syndrome.

In addition to being aetologic for classic Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome, germline PTEN mutations are being shown to be responsible for an increasing spectrum of clinical disorders. PTEN
mutations, which are responsible for the majority of cases of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome, have now been clearly shown to contribute to a subset of cases of Proteus syndrome and Proteus-like syndrome. In addition, germline PTEN mutations may account for the majority of patients with adult onset Lhermitte-Duclos disease, with or without the presence of other signs of Cowden syndrome in the patient. Thus, PTEN gene testing may be indicated in all cases of adult onset Lhermitte-Duclos disease. The contribution of PTEN mutations to cases with both macrocephaly and autism remains open to investigation, as do other aspects of this fascinating and evolving spectrum of disorders.

ACKNOWLEDGEMENTS

We would like to thank the patients and families who have participated in our studies, and the laboratory, collaborators, colleagues, and genetic counselors who have also contributed, in one way or another, to our research. J Med Genet 2004;41:323–326.

doi: 10.1136/jmg.2004.018036

Authors' affiliations

R Pilarski, Clinical Cancer Genetics Program, Comprehensive Cancer Center, Division of Human Genetics, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA

C Eng, Clinical Cancer Genetics Program and Human Cancer Genetics Program, Comprehensive Cancer Center, Division of Human Genetics, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA

C Eng, Cancer Research UK Human Cancer Genetics Research Group, University of Cambridge, UK

Conflicts of interest: none declared.

Correspondence to: Professor C Eng, Human Cancer Genetics Program, The Ohio State University, 420 W 11th Avenue, Ste 690 TMRF, Columbus, OH 43210, USA; eng@med.ohio-state.edu

Our research is partially funded by the National Cancer Institute (R21CA30722 to CE, P30CA16508 to the Comprehensive Cancer Center), the National Institutes of Health (RO1HD39538), American Cancer Society (RPG8–211–01–CCE and RSG02–151–01–CCE), Department of Defense US Army Breast and Prostate Cancer Research Programs (DAMD17–00–1–0390, DAMD17–02–1–0118, and DAMD17–02–1–0528), Susan G Komen Breast Cancer Research Foundation (BCTR 2000–462), an award from the Stephanie Spielman Breast Cancer Research Fund of the James Cancer Hospital and Solove Research Institute, and V Foundation (Jimmy V Golf Classic Award for Translational Cancer Research) (all to CE). CE is a recipient of the Doris Duke Distinguished Clinical Scientist Award.

REFERENCES


25 Delicakis MB, Danks A, Churchyard E, Xiou X-P, Eng C. De novo germline PTEN mutation in a man with Utermann-Duclos disease which arose on the paternal chromosome and was transmitted to his child with polydactyly and wormian bones. J Med Genet 2003;40:e72.

Cardiovascular genetics: are we there yet?

A C Sturm

doi: 10.1136/jmg.2003.017475

Updated information and services can be found at:
http://jmg.bmj.com/content/41/5/321

These include:

**References**
This article cites 24 articles, 8 of which you can access for free at:
http://jmg.bmj.com/content/41/5/321#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/